Sir,The recent report on detection of P53 and Mdm2 in vitiligo is very interesting.[1] Bakry et al. concluded that “The overexpression of P53 and Mdm2 proteins in both normally pigmented and depigmented skin of patients with vitiligo could contribute to the decreased occurrence of actinic damage and nonmelanoma skin cancer (NMSC) in these patients.”[1] There are many concerns on this work. First, the use of non-equal matched case control design might imply some bias. Also, there is no exclusion for the other possible underlying conditions that can cause alteration of P53 and Mdm2. Second, the quality control of the immunohistochemistry is very important. The bias in scoring system can also be expected. Standardization of the technique is still the issue for further improvement.[2]